drugset / Trial / NCT01153724
Relative Bioavailability of Olodaterol and Fluconazole
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is intended to investigate a possible effect of the CYP 2C9 inhibitor fluconazole on the bioavailability of olodaterol
Timeline
- Start
- 2010-05
- Primary completion
- 2010-07
- Completion
- —
Outcome
Missed primary endpoint
registry Adjusted geometric mean ratio 113.29 (90% CI 105.893 to 121.197); ANOVA; note: P-value for ratio outside interval 0.8-1.25 NCT01153724 ↗
registry Adjusted geometric mean ratio 108.78 (90% CI 101.590 to 116.487); ANOVA; note: P-value for ratio outside interval 0.8-1.25 NCT01153724 ↗
registry Adjusted geometric mean 85.98 (90% CI 79.277 to 93.253); ANOVA; note: P-value for ratio outside interval 0.8-1.25 NCT01153724 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluconazole | Small molecule | 400 mg | — |
| Subject | Olodaterol | Small molecule | 10 ug | Inhaled |